Clinical trials: Degenerative Neurologic Disease
Steinert's Disease
Compare Train and 3D-4D Left Ventricular Systolic Function in Subjects Suffering From Dystrophy and Healthy Subjects
Steinert's disease is an orphan disease. The prognosis of patients with this disease is conditioned by cardiac involvement. Search an early stage alterations in contractile function in subjects suffering from dystrophy would…
- Trial name
- NCT02930408
- Testing
- electrocardiogram, Echocardiography
- Volunteers
- 70 people
- Sponsor
- Poitiers University Hospital
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination.
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
- Trial name
- NCT05893225
- Testing
- Metformin Hydrochloride 850 mg Oral Tablet
- Where
- 5 sites in Belgium
- Volunteers
- 120 people
- Sponsor
- University Hospital, Antwerp
Parkinson Disease, Parkinsonian Syndrome
A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients
In this study, individuals complete and return a mail survey, specifically a 40 item scratch and sniff smell test.
- Trial name
- NCT00096876
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Myasthenia Gravis
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
This research is a single-center, exploratory, observational study to be carried out in the outpatient or inpatient ward of the Neurology Department at Huashan Hospital, affiliated to Fudan University.
- Trial name
- NCT07146425
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Alzheimer's Disease, Mild Cognitive Impairment
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected…
- Trial name
- NCT05040217
- Testing
- AAV2-BDNF Gene Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mark Tuszynski
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
1. To investigate the biomarkers of MND/FTD spectrum disease 2. To explore the possible pathogenesis of MND/FTD
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Motor Neuron Disease
- Trial name
- NCT04961450
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- Peking University Third Hospital
Alzheimer's Disease, Mild Cognitive Impairment
Alzheimer's Disease Core Center
The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
- Trial name
- ADCC (NCT01421420)
- Where
- United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Progressive Supranuclear Palsy
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT02985879
- Testing
- ABBV-8E12
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 378 people
- Sponsor
- AbbVie
AD, Early Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment [MCI] due to AD, or…
- Trial name
- NCT07252440
- Testing
- TTYP01 tables 60mg, TTYP01 tables 90mg, TTYP01 tables 0mg
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Multiple System Atrophy, Neurodegenerative Diseases
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
This is a randomized controlled parallel Group phase I study to investigate the safety and immunological/ therapeutic activity of two new vaccines, AFFITOPE® PD01A and AFFITOPE® PD03A, given to patients with early Multiple System…
- Trial name
- AFF009 (NCT02270489)
- Testing
- AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Affiris AG
Degenerative Disc Disease, Pain
Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration
Dr. Parker (the "Investigator") and Semmes Murphey Foundation ("Foundation") are conducting a study of outcomes and safety associated with degenerative discs at Semmes-Murphey Clinic, P.C. ("Semmes-Murphey").
- Trial name
- NCT02379689
- Testing
- Injectable placental tissue extract called BioDGenesis (Active Product)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Semmes-Murphey Foundation
Depression
Videoconferencing Acceptance and Commitment Therapy With a Web App Use for Family Caregivers of People With Dementia
The purpose of the pilot study is to assess the effects of an 8-week program on improving mental health in depressed family caregivers of people with dementia.
- Trial name
- NCT05518968
- Testing
- Acceptance and commitment therapy
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Parkinson Disease, Pain
Transcranial Alternating Current for Oscillopathies
The need for non-invasive, non-pharmacological and cost-effective therapeutic options has revived the use of transcranial current stimulation, either direct (tDCS) or alternating (tACS), in a wide range of pathologies and…
- Trial name
- tACS_EEG (NCT03221413)
- Testing
- transcranial alternating current stimulation (tACS)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Padova
Charcot-Marie-Tooth Disease
Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with Charcot-Marie-Tooth Disease Type 1 and Type X (CMT1 and CMTX), to…
- Trial name
- NCT03124459
- Testing
- ACE-083
- Where
- 16 sites in United States
- Volunteers
- 63 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Alzheimer s Disease, Alzheimer Dementia (AD)
Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs
This research proposal outlines a multi-center, randomized, trial. Patients diagnosed with early-to-moderate Alzheimer's Disease will be recruited. Participants will be randomly assigned to receive either Lecanemab.
- Conditions
- Alzheimer s Disease, Alzheimer Dementia (AD), MCI-AD, Early Stage Alzheimer's Disease
- Trial name
- NCT07604896
- Testing
- Lecanemab 10 mg/kg, Conventional anti-dementia treatment group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Parkinson Disease
Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
In this study the investigators will evaluate the effect of both low and high frequency Deep Brain stimulation of the subthalamic nucleus (STN) in Parkinson's patients who have noted a change in their walking.
- Trial name
- NCT00993291
- Testing
- Frequency change to 60 Hz, Frequency change to 130 Hz
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Parkinson Disease
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Ischemic conditioning (IC) is a promising therapy that can mimic the physiological effects of physical exercise. IC consists of using a cuff to measure blood pressure and calibrate 200 mmHg on the upper or lower limb.
- Trial name
- NCT06293118
- Testing
- Ischemic conditioning group
- Volunteers
- 50 people
- Sponsor
- Hospital Israelita Albert Einstein
Alzheimer's Disease
The Locus Coeruleus and Memory
The cause of Alzheimer's disease, the most common form of dementia, remains unknown. Neuropathological studies suggest that a small area in the brainstem, the locus coeruleus, might be the site of the onset of the disease.
- Trial name
- LOCUS (NCT02363504)
- Testing
- 7 Tesla MRI with memory task and non-invasive neurostimulation
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Mild Cognitive Impairment, Mild Dementia
Shanghai Non-pharmacological Intervention for Mild Cognitive Impairment and Mild Alzheimer's Disease
This study is a multicentre, randomized, double-blind, controlled trial that aims to investigate the efficacy of multi-domain life-style intervention including low inflammatory-index diet, exercise, and cognitive training in…
- Trial name
- SIM-2 (NCT05887674)
- Testing
- Diet intervention, Exercise, Cognitive training
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Ruijin Hospital
Alzheimer's Disease
Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672.
- Trial name
- NCT00490568
- Testing
- Rosiglitazone XR
- Where
- 272 sites in United States, Argentina and 27 more
- Volunteers
- 1,461 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.